Is Contineum Therapeutics, Inc. (CTNM) a Buy, Sell, or Hold?
NASDAQ : CTNM
Contineum Therapeutics, Inc.
$14.23 USD
$0.22 (1.57%)
- Volume
- 132.76K
- Average Volume
- 309.68K
- Market Capitalization
- $532.01M
- P/E Ratio
- -7.30
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $16.91
- Year Low
- $3.86
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $38.00
Company Overview
NASDAQ
Carmine N. Stengone
Biotechnology
Healthcare
CTNM
51
US
USD
Liquidity Metrics
0.03
38.00
38.00
3.03
0.00
Sales & Valuation
-$
0.00
2.12
-9.23
-1.54
Profitability
-$2.17
-$59.98M
0.00%
0.00%
-27.09%
-22.36%
P/E Metrics
-7.30
1.74
1.74
Analyst Price Target & Rating
$16.00
$16.00
$16.00
2/5
3 Analysts
-11.06%
Poll Results
About Contineum Therapeutics, Inc. (NASDAQ:CTNM) Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California. ...
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
2026-07-09 13:01:08
Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
2026-06-30 17:01:00
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the t
2026-06-30 16:05:00
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, “Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid R.
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
2026-06-01 16:05:00
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Co.
2026-05-25 10:56:17
The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
2026-05-22 08:04:21
Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist.
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 16:05:00
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stoc.
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-12 16:05:00
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th at 3:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section.
Frequently Asked Questions
-
What is the current Contineum Therapeutics, Inc. (CTNM) stock price?
-
Contineum Therapeutics, Inc.(NASDAQ:CTNM) stock price is $14.23 in the last trading session. During the trading session, CTNM stock reached the peak price of $16.91 while $3.86 was the lowest point it dropped to. The percentage change in CTNM stock occurred in the recent session was 1.57% while the dollar amount for the price change in CTNM stock was $0.22.
-
CTNM's industry and sector of operation?
-
The NASDAQ listed CTNM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CTNM?
-
Julie S. Iwashita | Senior Vice President of Clinical Operations
Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications
Timothy R. Watkins | Chief Medical Officer & Head of Development
Jennifer Patterson | Vice President of Human Resources
John Healy | General Counsel & Corporate Secretary -
How many employees does CTNM have?
-
Number of CTNM employees currently stands at 51. CTNM operates from 3565 General Atomics Court Suite 200, San Diego, CA 92121, US.
-
Link for CTNM official website?
-
Official Website of CTNM is: https://www.contineum-tx.com
-
How do I contact CTNM?
-
CTNM could be contacted at phone #(858) 333-5280 and can also be accessed through its website. CTNM operates from 3565 General Atomics Court Suite 200, San Diego, CA 92121, US.
-
How many shares of CTNM are traded daily?
-
The average number of CTNM shares traded daily for last 3 months was 309.68K.
-
What is the market cap of CTNM currently?
-
The market value of CTNM currently stands at $532.01M with its latest stock price at $14.23